Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664825 | 1.00 | CTSS (0.56) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922943 | 0.86 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4922934 | 0.86 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL7029037 | 0.86 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL17015 | 0.84 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4896150 | 0.84 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL3997764 | 0.84 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL4663069 | 0.84 | CTSS (0.57) | CTSSCTSKATMPTPN1SCN9A | |
| SCHEMBL3139804 | 0.84 | AAK1 (0.43) | CTSSCTSKATMPTPN1AAK1 | |
| SCHEMBL30753714 | 0.84 | CTSS (0.60) | CTSSCTSKATMPTPN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101001841-A | Tetrahydroquinolones and aza-analogues thereof useful as DPP-IV inhibitors for the treatment of diabetes | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | CTSS 1262/4885CTSK 786/4885ATM 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.